Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation

NCT01225211 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

312

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis

Interventions

DRUG: Lumacaftor
DRUG: Ivacaftor
DRUG: Lumacaftor Placebo
DRUG: Ivacaftor Placebo

Sponsor

Vertex Pharmaceuticals Incorporated